gene into a vector and expressing the PV L1 or PV L2 gene in a host cell.

8. The method according to Claim 6, wherein the one or more PV VLP genes comprise (i) a PV L1 VLP gene or (ii) a PV L1 VLP gene and a PV L2 VLP gene, wherein the vector is an expression vector, wherein the host cell is a cell from a permissive cell line.

9. The method according to Claim 6, wherein the permissive cell line is a Sf9 insect cell line and the expression vector is a baculovirus expression vector.

10. The method according to Claim 8, wherein the permissive cell line is a procaryotic cell line.

11. The method according to Claim 1, wherein the concentration of PV L1 VLPs or PV L1 VLPs and PV L2 VLPs administered to the patient is 0.5-20 μg.

12. The method according to Claim 11, wherein the concentration is 1-10 μg.

13. The method according to Claim 11 or 12, wherein the composition is administered 3-6 times over a period of 8-1 6 weeks.

14. The method according to Claim 11, wherein the composition is administered 3-6 times over a period of 2-4 weeks.

15. A method of immunization against HPV11 infection comprising administering HPV6 VLPs to a patient.

16. The method according to Claim 15, wherein the HPV6 VLPs are HPV6b VLPs.

17. The method according to Claim 15 or 16, wherein the concentration of the HPV6 VLPs are 0.5-20 μg.

18. The method according to Claim 17, wherein the concentration of the HPV6 VLPs are 1-10 μg.

19. The method according to Claim 17, wherein the HPV6 VLPs are administered 3-6 times over a period of 8-16 weeks.

20. The method according to Claim 17, wherein the HPV6 VLPs are administered 3-6 times over a period of 24 weeks.

21. A method of immunization against HPV6 infections comprising adiministering HPV11 VLPs to a patient.

22. The method according to Claim 21, wherein the concentration of the HPV11 VLPs is 0.5-20 μg.

23. The method according to Claim 22, wherein the concentration of the HPV11 VLPs is 1-10 μg.

24. The method of according to Claim 22 or 23, wherein the HPV11 VLPs are administered 3-6 times over a period of 8-16 weeks.

25. Method according to Claim 22 or 23, wherein the HPV11 VLPs are administered 3-6 times over a period of 2-4 weeks.

26. A method of treatment of an existing papillomavirus infection comprising administering papillomavirus VLPs without adjuvant to a patient suffering from the papillomavirus infection .

27. The method according to Claim 26, wherein the papillomavirus VLPs are chimeric.

28. The method according to Claim 26, wherein the papillomavirus VLPs comprise E protein.

29. The method according to Claim 1, wherein the composition further comprises an adjuvant.

30. The method according to Claim 29. wherein the adjuvant is one that induces cellular responses.

31. The method according to Claim 30, wherein the adjuvant is selected from the group consisting of (1) lipid A and derivatives, (2) Quillaia saponins and derivatives, (3) mycobacteria and components or derivatives therefrom, (4) IL 12, GMCSF, other Th1 inducting cytokines and (5) ozidized mannan and analogues thereof.

B7 32. The method according to Claim 1, wherein the composition lacks an adjuvant.